Brendan Eckelman, Ph.D., Founder

Chief Operating Officer & VP of Biotherapeutics

Brendan leads biotherapeutic development and scientific operations at Inhibrx. He oversees multiple groups, including discovery, protein sciences and biology. He has pioneered multiple innovative discovery and optimization platforms. In addition, Brendan has critical responsibilities in corporate strategy execution. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California San Diego School of Medicine.